1. Home
  2. ITRG vs BOLD Comparison

ITRG vs BOLD Comparison

Compare ITRG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

N/A

Current Price

$2.82

Market Cap

576.2M

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.83

Market Cap

60.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ITRG
BOLD
Founded
1997
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
576.2M
60.8M
IPO Year
2017
2024

Fundamental Metrics

Financial Performance
Metric
ITRG
BOLD
Price
$2.82
$2.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$5.13
$4.00
AVG Volume (30 Days)
2.7M
233.9K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$67.34
N/A
Revenue Next Year
$25.89
N/A
P/E Ratio
$45.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.99
$0.96
52 Week High
$4.87
$3.16

Technical Indicators

Market Signals
Indicator
ITRG
BOLD
Relative Strength Index (RSI) 62.88 59.74
Support Level $2.68 $2.71
Resistance Level $2.86 $2.97
Average True Range (ATR) 0.13 0.13
MACD 0.02 -0.02
Stochastic Oscillator 70.00 30.56

Price Performance

Historical Comparison
ITRG
BOLD

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: